Estrella Immunopharma Stock Today
| ESLA Stock | 1.14 0.10 9.62% |
Performance3 of 100
| Odds Of DistressLess than 50
|
Estrella Immunopharma is trading at 1.14 as of the 30th of November 2024, a 9.62% up since the beginning of the trading day. The stock's open price was 1.04. Estrella Immunopharma has 50 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Estrella Immunopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of September 2021 | Category Healthcare | Classification Health Care |
Estrella Immunopharma is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 36.18 M outstanding shares of which 14.56 K shares are currently shorted by private and institutional investors with about 0.07 trading days to cover. More on Estrella Immunopharma
Moving against Estrella Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Estrella Stock Highlights
| President CEO | Cheng Liu | ||||
| Old Names | [ESLA, ESLA, ESLA, ESLA] | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Financial Strength | |||||
Estrella Immunopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Estrella Immunopharma's financial leverage. It provides some insight into what part of Estrella Immunopharma's total assets is financed by creditors.
| |||||
Estrella Immunopharma (ESLA) is traded on NASDAQ Exchange in USA. It is located in 5858 Horton Street, EmeryVille, CA, United States, 94608 and employs 2 people. Estrella Immunopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.63 M. Estrella Immunopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.18 M outstanding shares of which 14.56 K shares are currently shorted by private and institutional investors with about 0.07 trading days to cover.
Estrella Immunopharma generates negative cash flow from operations
Check Estrella Immunopharma Probability Of Bankruptcy
Ownership AllocationEstrella Immunopharma holds a total of 36.18 Million outstanding shares. Estrella Immunopharma shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 72.06 percent of Estrella Immunopharma outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Estrella Ownership Details
Estrella Immunopharma Historical Income Statement
Estrella Stock Against Markets
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Estrella Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.24) | Return On Assets (1.22) | Return On Equity (2.78) |
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.